In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Asthmatx Breathes Easier

Executive Summary

Four-year old Asthmatx aims to be the first device company in asthma, a multi-billion dollar drug market. Asthmatx has run its Alair device, which reduces smooth muscle in the lung, through several clinical trials with an eye toward giving a choice to people suffering from the severest forms of the disease.
Advertisement

Related Content

Pulmonary Device Companies Take It To The Streets - In Europe
Asthmatx Acquisition By Boston Scientific Is Source of Many Happy Returns
Asthmatx Following the Leaders In Defining Alair Sales Strategy
Tighter FDA Review Squeezing Device VCs
Asthmatx Positive Panel Outcome Good Sign for Pulmonology Companies
CVRx: Can Devices Succeed Where Drugs Fail for High Blood Pressure?
CVRx: Can Devices Succeed Where Drugs Fail for High Blood Pressure?
Seizure Desist: Neurostim Companies Pursue Alternative Treatments for Epilepsy
Lung Cancer: An Up and Coming Device Market
Pulmonology: The Next Interventional Cardiology

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003000

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel